Determinants of hypomagnesemia in patients with type 2 diabetes mellitus

in European Journal of Endocrinology

Background

Hypomagnesemia (plasma magnesium (Mg2+) concentration <0.7 mmol/L) has been described in patients with type 2 diabetes. Polypharmacy is inevitable when treating a complex disease such as type 2 diabetes and could explain disturbances in the plasma Mg2+ concentration. In this study, we aimed to establish the extent of hypomagnesemia in a cohort of type 2 diabetes patients and to identify the determinants of plasma Mg2+ levels.

Methods

Patient data and samples of 395 type 2 diabetes patients were investigated. Plasma Mg2+ concentrations were measured using a spectrophotometric assay. Using Pearson correlation analyses, variables were correlated to plasma Mg2+ levels. After excluding confounding variables, all parameters correlating (P < 0.1) with plasma Mg2+ were included in a stepwise backward regression model.

Results

The mean plasma Mg2+ concentration in this cohort was 0.74 ± 0.10 mmol/L. In total, 121 patients (30.6%) suffered from hypomagnesemia. Both plasma triglyceride (r = −0.273, P < 0.001) and actual glucose levels (r = −0.231, P < 0.001) negatively correlated with the plasma Mg2+ concentration. Patients using metformin (n = 251, 62%), proton pump inhibitors (n = 179, 45%) or β-adrenergic receptor agonists (n = 31, 8%) displayed reduced plasma Mg2+ levels. Insulin use (n = 299, 76%) positively correlated with plasma Mg2+ levels. The model predicted (R2) 20% of all variance in the plasma Mg2+ concentration.

Conclusions

Hypomagnesemia is highly prevalent in type 2 diabetes patients. Plasma triglycerides and glucose levels are major determinants of the plasma Mg2+ concentration, whereas only a minor part (<10%) of hypomagnesemia can be explained by drug intake, excluding polypharmacy as a major cause for hypomagnesemia in type 2 diabetes.

Abstract

Background

Hypomagnesemia (plasma magnesium (Mg2+) concentration <0.7 mmol/L) has been described in patients with type 2 diabetes. Polypharmacy is inevitable when treating a complex disease such as type 2 diabetes and could explain disturbances in the plasma Mg2+ concentration. In this study, we aimed to establish the extent of hypomagnesemia in a cohort of type 2 diabetes patients and to identify the determinants of plasma Mg2+ levels.

Methods

Patient data and samples of 395 type 2 diabetes patients were investigated. Plasma Mg2+ concentrations were measured using a spectrophotometric assay. Using Pearson correlation analyses, variables were correlated to plasma Mg2+ levels. After excluding confounding variables, all parameters correlating (P < 0.1) with plasma Mg2+ were included in a stepwise backward regression model.

Results

The mean plasma Mg2+ concentration in this cohort was 0.74 ± 0.10 mmol/L. In total, 121 patients (30.6%) suffered from hypomagnesemia. Both plasma triglyceride (r = −0.273, P < 0.001) and actual glucose levels (r = −0.231, P < 0.001) negatively correlated with the plasma Mg2+ concentration. Patients using metformin (n = 251, 62%), proton pump inhibitors (n = 179, 45%) or β-adrenergic receptor agonists (n = 31, 8%) displayed reduced plasma Mg2+ levels. Insulin use (n = 299, 76%) positively correlated with plasma Mg2+ levels. The model predicted (R2) 20% of all variance in the plasma Mg2+ concentration.

Conclusions

Hypomagnesemia is highly prevalent in type 2 diabetes patients. Plasma triglycerides and glucose levels are major determinants of the plasma Mg2+ concentration, whereas only a minor part (<10%) of hypomagnesemia can be explained by drug intake, excluding polypharmacy as a major cause for hypomagnesemia in type 2 diabetes.

Introduction

Over the last decades, evidence is accumulating that hypomagnesemia (plasma Mg2+ concentration <0.7 mmol/L) is frequently present in patients with type 2 diabetes (1). Since its first report in the 1940s, hypomagnesemia has been shown in several cohort studies (2, 3, 4). Although plasma Mg2+ levels are not regularly monitored in type 2 diabetes patients, the presence of hypomagnesemia is of significant clinical importance (5). Oral Mg2+ supplementation has been shown to reduce the progression from pre-diabetes to diabetes and improves insulin sensitivity and glucose handling (3, 6, 7, 8). Moreover, in type 2 diabetes patients, hypomagnesemia results in a faster renal decline and is associated with a worse disease progression and outcome (9, 10). Mg2+ also plays a key role in common comorbidities of type 2 diabetes such as chronic kidney disease, atherosclerosis and hypertension (11, 12, 13, 14).

Hypomagnesemia can have many underlying causes, related or unrelated to type 2 diabetes (1, 15). First, hypomagnesemia can result from mutations in magnesiotropic genes, which has been extensively reviewed by Viering et al. (16). Second, the processing of food leads to a marked depletion of Mg2+ in the Western diet, resulting in a reduced dietary Mg2+ intake (17). Third, hypomagnesemia can be a result of impaired intestinal Mg2+ uptake due to diarrhea that could be induced by diabetic autonomic neuropathy or metformin use (18, 19, 20). Fourth, the use of certain medication (i.e. diuretics, immunosuppressive drugs, proton pump inhibitors (PPIs)) has been associated with hypomagnesemia (21). Lastly, metabolic acidosis and insulin resistance can decrease the expression of the renal Mg2+ channel transient receptor potential melastatin 6 (TRPM6), increasing urinary Mg2+ loss and thereby reducing the plasma Mg2+ concentration (22, 23).

The origin of hypomagnesemia in type 2 diabetes is currently unknown. The contributing factors to disturbed Mg2+ homeostasis may be multiple and have been poorly studied. Type 2 diabetes patients suffer from a wide range of clinical disturbances including increased plasma glucose concentrations, dyslipidemia (high triglyceride and low HDL cholesterol) and insulin resistance (24).

To maintain proper glucose levels and blood pressure, polypharmacy is an inevitable consequence of effectively treating type 2 diabetes. However, it also constitutes a growing risk factor as each drug carries its own side effects and drug–drug interactions (25). Potentially, the use of medication can contribute to hypomagnesemia. Several regularly prescribed drugs in type 2 diabetes are known to reduce the plasma Mg2+ levels, including PPIs and thiazide diuretics (26, 27, 28, 29, 30). However, it is unclear to what extent the hypomagnesemia in type 2 diabetes patients can be explained by the extensive use of medication.

In this study, we aimed to determine the prevalence of hypomagnesemia in a carefully phenotyped cohort of 402 type 2 diabetes patients. Subsequently, the determinants of plasma Mg2+ levels were analyzed using laboratory parameters and an extensive screening of drug use.

Subjects and methods

Subjects

Patients data and samples were taken from the Nijmegen-part of the Diabetes Pearl cohort (31). In short, 402 type 2 diabetes patients were included between June 2009 and February 2012 at the Radboud University Medical Center in Nijmegen, The Netherlands. Inclusion criteria were based on the WHO standards: a venous fasting plasma glucose concentration higher than 7.0 mmol/L or a casual venous plasma glucose concentration higher than 11.1 mmol/L (32). Personal information was obtained by dedicated patient questionnaires. This cohort consisted of patients under chronic secondary and tertiary care including many patients at an advanced disease stage.

Body mass index (BMI) was calculated as the weight in kilograms divided by square of the height in meters. Blood pressure and heart rate were measured in triplicate, and the average value was used in subsequent analyses. Waist circumference was measured in duplicate after normal exhalation and if the difference between these two measurements was >1.0 cm, the measurement was repeated for a third time. Plasma and urine samples were taken after an overnight fasting period. The samples were analyzed for laboratory parameters (glycated hemoglobin (HbA1c), plasma glucose, creatinine, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides) and immediately stored at −80°C for further analyses. A detailed description of the patient characteristics is reported in Table 1.

Table 1

Characteristics of type 2 diabetes patients.

VariableMean ± s.d.RangeReference value
Demographics
 Gender (m:f, %)59:41
 BMI (kg/m2)32.6 ± 6.517–6118.5–25
 Age (years)67 ± 1034–90
 Duration diabetes (years)15.8 ± 9.50–56
 Waist circumference (m:f, cm)110 ± 1665–152<102:<88
 SBP (mmHg)143 ± 2084–20790–140
 DBP (mmHg)77 ± 1151–11760–90
 Heart rate (beats/min)73 ± 1245–11660–100
 Alcohol consumption (no:yes, %)52:48
Laboratory analyses
 Total cholesterol (mmol/L)4.5 ± 1.52.0–20.0<5.2
 Triglycerides (mmol/L)2.5 ± 4.10.4–50.7<1.7
 HbA1c (mmol/mol)63.1 ± 14.233.3–118.6<42
 Glucose (mmol/L)9.4 ± 3.42.3–24.93.9–5.5
 LDL (mmol/L)2.3 ± 0.80.6–4.9<2.6
 HDL (m:f, mmol/L)1.1 ± 0.30.5–2.2>1.1:>1.3

BMI, body mass index; DBP, diastolic blood pressure; f, female; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; m, male; SBP, systolic blood pressure.

Participants were requested to bring all their medication on the day of the visit or lists from pharmacists to score their medication use accurately. Medication was classed into groups according to the Anatomical Therapeutic Chemical Classification System (ATC) for statistical analysis (Table 2). The study was performed according to the Declaration of Helsinki. All patients provided written informed consent. All study investigators had access to the study data, and they reviewed and approved the final manuscript.

Table 2

Medication use of type 2 diabetes patients.

MedicationNumber of patients (n = 395)Percentage
ACE inhibitor18747.3
ANGIIR antagonist9524.1
β-Adrenergic agonist317.8
β-Adrenergic antagonist20952.9
Calcium channel blocker8822.3
Insulin29975.7
K+-saving diuretic4812.2
Loop diuretic7519.0
Metformin25163.5
Nitrate5413.7
PPI17945.3
Statin29374.2
Sulfonylureum7719.5
Thiazide diuretic12832.4

ACE, angiotensin-converting enzyme; ANGIIR, angiotensin II receptor; PPI, proton pump inhibitor.

Measures

This study was designed as an observational cohort study using samples from the existing Diabetes Pearl cohort biobank (31). Laboratory values (fasting) and use of medication of 402 patients were examined at the inclusion date. Seven patients were excluded because of insufficient sample availability. Not only Mg2+ but also sodium (Na+) and potassium (K+) concentrations were measured in the stored plasma and urine samples from the biobank. Fasting plasma Mg2+ concentrations were determined using a spectrophotometric assay (Roche/Hitachi) and measured at 600 nm on a Bio-Rad Benchmark plus microplate spectrophotometer (Bio-Rad Laboratories), according to the manufacturer’s protocol. Fasting plasma Na+, K+ and creatinine and urinary Mg2+, Na+, K+ and creatinine concentrations were measured at the clinical chemistry department using standardized methods. The fractional excretion of Mg2+ (FEMg) was calculated according to the formula (UMg × Screa)/(Ucrea × SMg) × 70 (33). GFR was estimated (eGFR) using the ‘Modification of Diet in Renal Disease’ (MDRD) formula: 186 × plasma creatinine−1.154 × age−0.203 × 1.210 (if black) × 0.742 (if female) (34). Patients with an eGFR <30 mL/min were excluded from subsequent urinary analyses.

Statistical analysis

Data are presented as mean ± standard deviation (s.d.). Pearson’s correlation tests were performed to determine the association between plasma Mg2+ concentration and clinical and anthropomorphic parameters. HbA1c and plasma values of triglycerides, glucose, LDL, HDL and total cholesterol were log10 transformed before use in statistical analyses. All variables with a P value <0.1 in the Pearson’s correlation analyses, not corrected for multiple testing, were checked for confounding by performing partial regression analyses. Variables that correlated to plasma Mg2+ concentration with P < 0.1, after correcting for confounding, were included in the stepwise multivariate backward elimination model. In this model, variables with P > 0.1 were eliminated. All statistical analyses were performed using SPSS for Windows (V22.0.0.1 IBM). A P value of <0.05 was considered statistically significant.

Results

Study population

In total, 395 type 2 diabetes patients were included in the study cohort. Clinical characteristics and laboratory results are provided in Table 1. This is a group of patients with longstanding diabetes, mostly on insulin treatment with an extensive use of medication (Table 2). The average plasma Mg2+ concentration in the cohort was 0.74 ± 0.10 mmol/L, and a total of 121 patients (30.6%) had levels below 0.70 mmol/L, indicating hypomagnesemia (Fig. 1). Hypermagnesemia was found in 1 patient. Plasma Na+ and K+ levels were normally distributed in the reference range (Supplementary Fig. 1, see section on supplementary data given at the end of this article).

Figure 1

Download Figure

Figure 1

Hypomagnesemia in type 2 diabetes patients. The plasma Mg2+ concentration was determined in 395 type 2 diabetes patients. Hypomagnesemia was observed in 30.6% of the patients. Bars represent the number of patients. Dotted vertical lines indicate the normal range (0.7–1.1 mmol/L).

Citation: European Journal of Endocrinology 176, 1; 10.1530/EJE-16-0517

Determinants of the plasma Mg2+ concentration

Using univariate regression analyses, a correlation between plasma Mg2+ concentration and several clinical characteristics was demonstrated: BMI (r = −0.162, P = 0.001), waist circumference (r = −0.158, P = 0.002), diastolic blood pressure (DBP, r = −0.144, P = 0.004), heart rate (r = −0.104, P = 0.039), eGFR (r = −0.168, P = 0.001), HbA1c (r = −0.123, P = 0.015) and plasma levels of triglycerides (r = −0.273, P < 0.001) and glucose (r = −0.231, P < 0.001) negatively correlated with the plasma Mg2+ concentration. In contrast, the duration of diabetes (r = 0.139, P = 0.008) and the plasma level of HDL (r = 0.156, P = 0.002) and Na+ (r = 0.108, P = 0.032) were correlated with an increased plasma Mg2+ concentration (Table 3).

Table 3

Univariate analyses for correlation of patient characteristics on plasma Mg2+ concentration.

VariablePearson’s correlation coefficientP valuen
Demographics
 Gender0.0070.897395
 BMI (kg/m2)−0.1620.001394
 Age (years)0.0890.076395
 Duration diabetes (years)0.1390.008365
 Waist circumference (cm)−0.1580.002392
 SBP (mmHg)−0.0560.269395
 DBP (mmHg)−0.1440.004395
 Heart rate (beats/min)−0.1040.039395
 Alcohol consumption (no/yes)−0.0040.680390
Laboratory analyses
 eGFR (mL/min)−0.1680.001371
 Log10 HDL (mmol/L)0.1560.002387
 Log10 total cholesterol (mmol/L)−0.0590.247388
 Log10 HbA1c (mmol/mol)−0.1230.015391
 Log10 triglycerides (mmol/L)−0.273<0.001387
 Log10 glucose (mmol/L)−0.231<0.001383
 Log10 LDL (mmol/L)0.0770.145365
 Plasma Na+ (mmol/L)0.1080.032391
 Plasma K+ (mmol/L)0.0810.110394
Medication
 ACE inhibitor−0.0940.063
 ANGIIR antagonist0.0370.469
 β-Adrenergic agonist−0.1030.041
 β-Blocker−0.0560.270
 Calcium channel blocker−0.0720.155
 Insulin0.1090.030
 K+-saving diuretic−0.0230.685
 Loop diuretic0.0720.153
 Metformin−0.268<0.001
 Nitrate−0.0430.389
 PPI−0.0840.094
 Statin0.0020.962
 Sulfonylureum−0.0440.382
 Thiazide diuretic−0.0840.104

ACE, angiotensin-converting-enzyme; ANGIIR, angiotensin II receptor; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low density lipoprotein; PPI, proton pump inhibitor; SBP, systolic blood pressure.

The effect of drug use was specifically analyzed. The use of metformin (r = −0.268, P < 0.001) or β-adrenergic receptor agonists (r = −0.103, P = 0.041) negatively correlated with plasma Mg2+, whereas use of insulin (r = 0.109, P = 0.030) was associated with higher plasma Mg2+ levels.

Confounding factors were identified using partial correlation analyses and excluded from subsequent analysis (Supplementary Tables 1, 2, 3). After correction for confounding, all parameters correlating (P < 0.1) with plasma Mg2+ univariately, were included in the stepwise backward regression analysis model (Table 4). In this model, parameters with a P value >0.1 were eliminated (BMI, DBP and angiotensin-converting enzyme (ACE) inhibitors). In the final model, plasma levels of glucose and triglycerides, as well as the use of PPIs, metformin or β-adrenergic receptor agonists negatively predicted plasma Mg2+ levels. Interestingly, patients on insulin had a trend (P = 0.053) toward having higher plasma Mg2+ levels than people not on insulin. Altogether, the model predicted (R2) 20% of the plasma Mg2+ concentration.

Table 4

Stepwise backward regression analysis on plasma Mg2+ concentration.

VariableCoefficientP valueRange
Log10 triglycerides (mmol/L)−0.073<0.001−0.113 to −0.033
Log10 glucose (mmol/L)−0.149<0.001−0.216 to −0.082
eGFR (mL/min)0.0000.022−0.001 to 0.000
PPI*−0.0230.022−0.043 to −0.003
Metformin*−0.044<0.001−0.065 to −0.023
Insulin*0.0230.0530.000–0.046
β-Adrenergic agonist*−0.0470.009−0.082 to −0.012

All variables with a P > 0.1 were excluded from the model.

*No: 0, Yes: 1. eGFR, estimated glomerular filtration rate; PPI, proton pump inhibitor.

Increased urinary Mg2+ excretion

To investigate whether the hypomagnesemia is explained by renal Mg2+ loss, the fractional excretion of Mg2+ (FEMg) was determined. The mean FEMg in the cohort was 3.9 ± 2.7%. In total, 148 patients (40.8%) suffered from renal Mg2+ wasting, defined as FEMg >4%. Nevertheless, FEMg was not significantly different (P = 0.75) between normomagnesemic patients (3.9 ± 2.8%) and hypomagnesemic patients (3.9 ± 2.5%) (Fig. 2).

Figure 2

Download Figure

Figure 2

Increased FEMg in type 2 diabetes patients. The fractional excretion of Mg2+ (FEMg) was determined in 369 type 2 diabetes patients, of which 259 were normomagnesemic (A) and 110 were hypomagnesemic (B). Bars represent the percentage of the population. Dotted vertical lines indicate the threshold for urinary Mg2+ wasting (FEMg >4%).

Citation: European Journal of Endocrinology 176, 1; 10.1530/EJE-16-0517

Discussion

This study further substantiates the high prevalence of hypomagnesemia in type 2 diabetes. A negative correlation between plasma Mg2+ concentration and the plasma glucose and triglycerides levels was demonstrated. In addition, polypharmacy could be excluded as the main cause of hypomagnesemia in type 2 diabetes patients as only less than ten percent of changes in plasma Mg2+ could be attributed to medication use. These findings suggest that hypomagnesemia in type 2 diabetes patients is intrinsic to the disease.

Hypomagnesemia was observed in 30.6% of the patients, corresponding to incidence numbers of 13.5–47.7% observed in previous cohort studies (3, 4, 35, 36). In comparison, in a large study of 5179 subjects aged 55 and older, the incidence of hypomagnesemia was only 2%, highlighting the extensive amount of hypomagnesemia diabetes mellitus type 2 patients (10). Given that hypomagnesemia is related to a faster disease progression and an increased risk of diabetes-related complications, such as renal failure and cardiovascular disease, it is of great clinical importance to identify the factors that determine plasma Mg2+ concentrations (1, 9, 13, 37). Therefore, we constructed a statistical model that includes the factors influencing plasma Mg2+ levels. Twenty percent of the variation in plasma Mg2+ concentration is explained by our model containing eGFR, the plasma concentrations of glucose and triglycerides and the use of PPIs, insulin, metformin and β-adrenergic receptor agonists. Although this is only a modest part of the total variation, it is comparable to the effect of dietary Mg2+ intake and higher than current genetic models, which explain 25–30% and 1–5% of changes in the plasma Mg2+ concentration respectively (38, 39, 40). The finding that in our model most of the variance in plasma Mg2+ can be explained by factors that determine metabolic control underlines the importance of glucose and lipid homeostasis in the regulation of plasma Mg2+ levels.

Plasma glucose and triglyceride levels were the main determinants of plasma Mg2+ concentrations in our model. This correlation was independent of obesity-related factors such as waist circumference, BMI and cholesterol. Previous studies investigating metabolic syndrome have shown an association between triglycerides and Mg2+ levels (41, 42). However, these studies did not investigate the collinearity between triglycerides and HDL or were not based on the plasma Mg2+ concentration. Mg2+ supplementation is generally considered to improve the lipid profile in patients; however, studies addressing the effect of Mg2+ on plasma triglyceride concentrations are inconsistent (43, 44). As Mg2+ increases the affinity of the insulin receptor tyrosine kinase for ATP, the decreased plasma Mg2+ levels could exacerbate insulin resistance in type 2 diabetes patients, and thereby increase plasma glucose and triglyceride concentrations (45, 46).

Medication could only explain a minor part of the changes in plasma Mg2+ concentration in type 2 diabetes patients (<10%), showing that polypharmacy is not the primary cause of hypomagnesemia in type 2 diabetes patients. Known hypomagnesemia-causing drugs, β-adrenergic receptor agonists and PPIs negatively correlated with the plasma Mg2+ concentration, although with minor effect sizes (<2%) (30, 47, 48, 49). Of all drugs, the use of metformin was most strongly correlated (r = −0.268, P < 0.001) with the plasma Mg2+ concentration, irrespective of eGFR or fasting glucose levels. Our study is the first large cohort study to identify the association between the use of metformin and plasma Mg2+ levels. A few studies with limited patient numbers from the 70s and 80s suggested that treating patients with metformin reduces plasma Mg2+ levels (4, 50). How metformin affects Mg2+ handling remains to be elucidated. In contrast, patients taking insulin had a trend (P = 0.053) toward higher plasma Mg2+ levels than those who did not require insulin treatment. This is in concordance with experimental studies showing that insulin stimulates the renal Mg2+ channel TRPM6, resulting in increased renal Mg2+ reabsorption (23). Therefore, despite their worse glycemic control, patients on insulin treatment have slightly better plasma Mg2+ values than metformin-treated patients. These results suggest that the positive renal effect of insulin on the reabsorption of Mg2+ overrides the negative effect of poor glycemic control of insulin-dependent patients on their Mg2+ levels.

We observed that high renal Mg2+ excretion is prevalent among type 2 diabetes patients, with 41% of the patients in the cohort having a FEMg >4%. Although these findings suggest that impaired renal Mg2+ reabsorption contributes to hypomagnesemia in type 2 diabetes patients, renal Mg2+ wasting was equally frequent in hypomagnesemic and normomagnesemic patients. Hypomagnesemia only arises when body Mg2+ stores, such as bone, are depleted (51). Therefore, hypomagnesemia may only develop after several years, despite increased renal Mg2+ excretion. Our findings of overall high Mg2+ excretion may thus indicate that the complete diabetic population is at risk to develop hypomagnesemia. FEMg was not related to fasting glucose levels (data not shown), showing that diabetes severity does not influence the amount of urinary Mg2+ loss.

The strength of our study is the thorough and extensive phenotyping of the diabetes patients, allowing systematic investigation of the contribution of polypharmacy and metabolism-related parameters to changes in the plasma Mg2+ concentration of type 2 diabetes patients. By carefully collecting data on drug use, this is the first cohort study that determined the contribution of medication usage to changes in plasma Mg2+ concentrations. The availability of urine samples enabled the determination of the FEMg in a large cohort of severe type 2 diabetes patients for the first time.

However, several limitations have to be considered. First, data on the dietary habits of the participants was not collected, excluding the potential effects of diet from our analyses. However, the influence of diet on plasma Mg2+ levels will be minor, as samples were collected after an overnight fast. Secondly, all the samples were collected at a single point, and no follow-up data are available. Therefore, the observed correlations will not provide information about causality. A final limitation is the fact that the extent of insulin resistance was not directly determined. However, several studies have proposed that the product of fasting glucose and triglycerides can be used as a measure to estimate insulin resistance (52, 53). The strong correlation of plasma Mg2+ with glucose and triglycerides in our study therefore provides an indirect link with insulin resistance.

In conclusion, this study shows that hypomagnesemia is a prominent feature of type 2 diabetes, and is supported by excessive urinary Mg2+ loss. We excluded polypharmacy as the major cause of changes in plasma Mg2+ concentration in type 2 diabetes patients. Given that metabolic factors such as glucose and triglyceride concentrations are main determinants of the plasma Mg2+ concentration, Mg2+ disturbances should be considered and, if required, corrected in type 2 diabetes patients.

Supplementary data

This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-16-0517.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This study was supported by funding from the Radboud Institute for Molecular Life Science and by grants from the Netherlands Organization for Scientific Research (NWO VICI 016.130.668) and the EURenOmics project from the European Union seventh Framework Programme (FP7/2007–2013, agreement no. 305608) to J H. J H F B is supported by grants from NWO (Rubicon 825.14.021) and the Dutch Kidney Foundation (Kolff grant 14OKG17).

Author contribution statement

Data were collected by S K and H B. Statistical analysis was done by S K. Manuscript was written by S K, J B, R B, C T and J H, and it was supervised by J B, R B, C T and J H. All authors have read and approved the final version of the manuscript. J H is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgements

The authors are greatly indebted to all the patients of the Diabetes Pearl cohort and like to thank Dick Thijssen and Martijn Maessen (Department of Physiology, Radboudumc Nijmegen), and Jan van den Brand (Department of Nephrology, Radboudumc Nijmegen) for their insights in the statistical analyses. Marlies Fennis (Department of Physiology, Radboudumc Nijmegen), Anja Rasing-Hoogveld, Evertine Abbink (Clinical Research Centre, Radboudumc Nijmegen) and Rob Verheyen (Department of Theoretical High Energy Physics, Radboud University Nijmegen) for their excellent technical support.

References

  • 1

    GommersLMHoenderopJGBindelsRJde BaaijJH.Hypomagnesemia in type 2 diabetes: a vicious circle?Diabetes201665313. (doi:10.2337/db15-1028)

  • 2

    MartinHEWertmanM.Serum potassium, magnesium, and calcium levels in diabetic acidosis. Journal of Clinical Investigation194726217228. (doi:10.1172/JCI101799)

  • 3

    PhamPCPhamPMPhamSVMillerJMPhamPT.Hypomagnesemia in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology20072366373. (doi:10.2215/CJN.02960906)

  • 4

    MatherHMNisbetJABurtonGHPostonGJBlandJMBaileyPAPilkingtonTR.Hypomagnesaemia in diabetes. Clinica Chimica Acta197995235242. (doi:10.1016/0009-8981(79)90364-4)

  • 5

    GroberUSchmidtJKistersK.Magnesium in prevention and therapy. Nutrients2015781998226. (doi:10.3390/nu7095388)

  • 6

    Guerrero-RomeroFTamez-PerezHEGonzalez-GonzalezGSalinas-MartinezAMMontes-VillarrealJTrevino-OrtizJHRodriguez-MoranM.Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes and Metabolism200430253258. (doi:10.1016/S1262-3636(07)70116-7)

  • 7

    PaolissoGSgambatoSGambardellaAPizzaGTesauroPVarricchioMD’OnofrioF.Daily magnesium supplements improve glucose handling in elderly subjects. American Journal of Clinical Nutrition19925511611167.

  • 8

    HrubyAMeigsJBO’DonnellCJJacquesPFMcKeownNM.Higher magnesium intake reduces risk of impaired glucose and insulin metabolism and progression from prediabetes to diabetes in middle-aged americans. Diabetes Care201437419427. (doi:10.2337/dc13-1397)

  • 9

    PhamPCPhamPMPhamPAPhamSVPhamHVMillerJMYanagawaNPhamPT.Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clinical Nephrology200563429436. (doi:10.5414/CNP63429)

  • 10

    LiamisGRodenburgEMHofmanAZietseRStrickerBHHoornEJ.Electrolyte disorders in community subjects: prevalence and risk factors. American Journal of Medicine2013126256263. (doi:10.1016/j.amjmed.2012.06.037)

  • 11

    PeacockJMFolsomARArnettDKEckfeldtJHSzkloM.Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Annals of Epidemiology19999159165. (doi:10.1016/S1047-2797(98)00040-4)

  • 12

    MaJFolsomARMelnickSLEckfeldtJHSharrettARNabulsiAAHutchinsonRGMetcalfPA.Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. Journal of Clinical Epidemiology199548927940. (doi:10.1016/0895-4356(94)00200-A)

  • 13

    de Roij van ZuijdewijnCLGrootemanMPBotsMLBlankestijnPJSteppanSBuchelJGroenwoldRHBrandenburgVvan den DorpelMATer WeePMSerum magnesium and sudden death in European hemodialysis patients. PLoS ONE201510e0143104. (doi:10.1371/journal.pone.0143104)

  • 14

    MassyZADruekeTB.Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clinical Kidney Journal20125i52i61. (doi:10.1093/ndtplus/sfr167)

  • 15

    LiamisGLiberopoulosEBarkasFElisafM.Diabetes mellitus and electrolyte disorders. World Journal of Clinical Cases20142488496. (doi:10.12998/wjcc.v2.i10.488)

  • 16

    VieringDHde BaaijJHWalshSBKletaRBockenhauerD.Genetic causes of hypomagnesemia, a clinical overview.Pediatric Nephrology2016. In press. (doi:10.1007/s00467-016-3416-3)

  • 17

    MarierJR.Magnesium content of the food supply in the modern-day world. Magnesium1986518.

  • 18

    FossMTClementKD.Metformin as a cause of late-onset chronic diarrhea. Pharmacotherapy20012114221424. (doi:10.1592/phco.21.17.1422.34430)

  • 19

    SvareA.A patient presenting with symptomatic hypomagnesemia caused by metformin-induced diarrhoea: a case report. Cases Journal20092156. (doi:10.1186/1757-1626-2-156)

  • 20

    VinikAIMaserREMitchellBDFreemanR.Diabetic autonomic neuropathy. Diabetes Care20032615531579. (doi:10.2337/diacare.26.5.1553)

  • 21

    LamerisALMonnensLABindelsRJHoenderopJG.Drug-induced alterations in Mg2+ homoeostasis. Clinical Science2012123114. (doi:10.1042/CS20120045)

  • 22

    NijenhuisTRenkemaKYHoenderopJGBindelsRJ.Acid-base status determines the renal expression of Ca2+ and Mg2+ transport proteins. Journal of the American Society of Nephrology200617617626. (doi:10.1681/ASN.2005070732)

  • 23

    NairAVHocherBVerkaartSvan ZeelandFPfabTSlowinskiTChenYPSchlingmannKPSchallerAGallatiSLoss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. PNAS20121091132411329. (doi:10.1073/pnas.1113811109)

  • 24

    WilcoxG.Insulin and insulin resistance. Clinical Biochemist Reviews2005261939.

  • 25

    NyenweEAJerkinsTWUmpierrezGEKitabchiAE.Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism201160123. (doi:10.1016/j.metabol.2010.09.010)

  • 26

    DeFronzoRACookeCRAndresRFaloonaGRDavisPJ.The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. Journal of Clinical Investigation197555845855. (doi:10.1172/JCI107996)

  • 27

    NijenhuisTVallonVvan der KempAWLoffingJHoenderopJGBindelsRJ.Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. Journal of Clinical Investigation200511516511658. (doi:10.1172/JCI24134)

  • 28

    MartinBJMilliganK.Diuretic-associated hypomagnesemia in the elderly. Archives of Internal Medicine198714717681771. (doi:10.1001/archinte.1987.00370100082014)

  • 29

    CohenNAlmoznino-SarafianDZaidensteinRAlonIGorelikOShteinshnaiderMChachashvilySAverbukhZGolikAChen-LevyZModaiD.Serum magnesium aberrations in furosemide (frusemide) treated patients with congestive heart failure: pathophysiological correlates and prognostic evaluation. Heart200389411416. (doi:10.1136/heart.89.4.411)

  • 30

    HessMWHoenderopJGBindelsRJDrenthJP.Systematic review: hypomagnesaemia induced by proton pump inhibition. Alimentary Pharmacology and Therapeutics201236405413. (doi:10.1111/j.1365-2036.2012.05201.x)

  • 31

    van’tRiet ESchramMTAbbinkEJAdmiraalWMDijk-SchaapMWHollemanFNijpelsGOzcanBPijlHSchaperNCThe diabetes pearl: diabetes biobanking in The Netherlands. BMC Public Health201212949. (doi:10.1186/1471-2458-12-949)

  • 32

    OrganizationWH.Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. Geneva, Switzerland: World Health Org, 2006.

  • 33

    AyukJGittoesNJ.Contemporary view of the clinical relevance of magnesium homeostasis. Annals of Clinical Biochemistry201451179188. (doi:10.1177/0004563213517628)

  • 34

    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases200239S1S266.

  • 35

    de Lordes LimaMCruzTPousadaJCRodriguesLEBarbosaKCangucuV.The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care199821682686. (doi:10.2337/diacare.21.5.682)

  • 36

    McNairPChristensenMSChristiansenCMadsbadSTransbolI.Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasis. European Journal of Clinical Investigation1982128185. (doi:10.1111/j.1365-2362.1982.tb00942.x)

  • 37

    BoSPisuE.Role of dietary magnesium in cardiovascular disease prevention, insulin sensitivity and diabetes. Current Opinion in Lipidology2008195056. (doi:10.1097/MOL.0b013e3282f33ccc)

  • 38

    TinAKottgenAFolsomARMaruthurNMTajuddinSMNallsMAEvansMKZondermanABFriedrichCABoerwinkleEGenetic loci for serum magnesium among African–Americans and gene–environment interaction at MUC1 and TRPM6 in European–Americans: the Atherosclerosis Risk in Communities (ARIC) study. BMC Genetics20151656. (doi:10.1186/s12863-015-0219-7)

  • 39

    MeyerTEVerwoertGCHwangSJGlazerNLSmithAVvan RooijFJEhretGBBoerwinkleEFelixJFLeakTSGenome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels.PLoS Genetics20106. (doi:10.1371/journal.pgen.1001045)

  • 40

    AkizawaYKoizumiSItokawaYOjimaTNakamuraYTamuraTKusakaY.Daily magnesium intake and serum magnesium concentration among Japanese people. Journal of Epidemiology200818151159. (doi:10.2188/jea.JE2007381)

  • 41

    CoricaFCorsonelloAIentileRCucinottaDDi BenedettoAPerticoneFDominguezLJBarbagalloM.Serum ionized magnesium levels in relation to metabolic syndrome in type 2 diabetic patients. Journal of the American College of Nutrition200625210215. (doi:10.1080/07315724.2006.10719534)

  • 42

    Guerrero-RomeroFRodriguez-MoranM.Low serum magnesium levels and metabolic syndrome. Acta Diabetologica200239209213. (doi:10.1007/s005920200036)

  • 43

    LalJVasudevKKelaAKJainSK.Effect of oral magnesium supplementation on the lipid profile and blood glucose of patients with type 2 diabetes mellitus. Journal of the Association of Physicians of India2003513742.

  • 44

    SongYHeKLevitanEBMansonJELiuS.Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabetic Medicine20062310501056. (doi:10.1111/j.1464-5491.2006.01852.x)

  • 45

    VinalsFCampsMTestarXPalacinMZorzanoA.Effect of cations on the tyrosine kinase activity of the insulin receptor: inhibition by fluoride is magnesium dependent. Molecular and Cellular Biochemistry19971716973. (doi:10.1023/A:1006836001489)

  • 46

    VicarioPPBennunA.Separate effects of Mg2+, MgATP, and ATP4- on the kinetic mechanism for insulin receptor tyrosine kinase. Archives of Biochemistry and Biophysics199027899105. (doi:10.1016/0003-9861(90)90236-R)

  • 47

    CheungpasitpornWThongprayoonCKittanamongkolchaiWSrivaliNEdmondsPJUngprasertPO’CorragainOAKorpaisarnSEricksonSB.Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Renal Failure20153712371241. (doi:10.3109/0886022X.2015.1057800)

  • 48

    FaganTERomaniA.Activation of Na(+)- and Ca(2+)-dependent Mg(2+) extrusion by alpha(1)- and beta-adrenergic agonists in rat liver cells. American Journal of Physiology: Gastrointestinal and Liver Physiology2000279G943G950.

  • 49

    LipworthBJMcDevittDGStruthersAD.Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. American Journal of Medicine198986653657. (doi:10.1016/0002-9343(89)90438-5)

  • 50

    McBainAMBrownIRMenziesDGCampbellIW.Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes. Journal of Clinical Pathology198841933935. (doi:10.1136/jcp.41.9.933)

  • 51

    SwaminathanR.Magnesium metabolism and its disorders. Clinical Biochemist Reviews2003244766.

  • 52

    Simental-MendiaLERodriguez-MoranMGuerrero-RomeroF.The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metabolic Syndrome and Related Disorders20086299304. (doi:10.1089/met.2008.0034)

  • 53

    Guerrero-RomeroFSimental-MendiaLEGonzalez-OrtizMMartinez-AbundisERamos-ZavalaMGHernandez-GonzalezSOJacques-CamarenaORodriguez-MoranM.The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. Journal of Clinical Endocrinology and Metabolism20109533473351. (doi:10.1210/jc.2010-0288)

 

Official journal of

European Society of Endocrinology

Sections

Figures

  • View in gallery

    Hypomagnesemia in type 2 diabetes patients. The plasma Mg2+ concentration was determined in 395 type 2 diabetes patients. Hypomagnesemia was observed in 30.6% of the patients. Bars represent the number of patients. Dotted vertical lines indicate the normal range (0.7–1.1 mmol/L).

  • View in gallery

    Increased FEMg in type 2 diabetes patients. The fractional excretion of Mg2+ (FEMg) was determined in 369 type 2 diabetes patients, of which 259 were normomagnesemic (A) and 110 were hypomagnesemic (B). Bars represent the percentage of the population. Dotted vertical lines indicate the threshold for urinary Mg2+ wasting (FEMg >4%).

Index Card

Cited By

PubMed

Google Scholar

Related Articles

Altmetrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 414 414 124
PDF Downloads 76 76 25